Jun 2026 (Q2 FY26) — Aug 11, 2026
Fennec Pharmaceuticals Q2 FY26 — Record PEDMARC Demand and Strong Commercial Momentum
Read the full callFennec Pharmaceuticals (FENC) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Fennec Pharmaceuticals earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 17.9 | +85.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 9.7 | +38.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 2.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$10.27 +2.91% · +$0.29
Performance +24.6% 1Y
1Y: $8.24 on 17 Oct 2025 → $10.27. High $12.78 (11 Aug 2026), low $5.77 (30 Mar 2026).
- Previous close
- $9.98
- 52-week range
- $5.77 – $12.78
- One year
- +18.59%
Overview
- Symbol
- FENC
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Fennec Pharmaceuticals earnings calls (FENC)
Financials
What the filings say
Net profit, year on year: +163% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7 | 8 | 9 | 10 | 12 | 14 | 15 | 18 |
| Operating profit | -5 | -1 | -1 | -3 | -0 | -3 | -0 | 2 |
| Operating margin | −74.6% | −11.8% | −9.2% | −28.3% | −1.5% | −18.5% | −0.8% | 9.7% |
| Other income | -1 | -1 | -0 | -0 | -0 | -2 | 0 | 0 |
| Profit before tax | — | — | — | -3 | — | — | — | 2 |
| Tax rate | — | — | — | — | — | — | — | 2.1% |
| Net profit | -6 | -2 | -1 | -3 | -1 | -5 | 0 | 2 |
| EPS ($ per share) | -0.21 | — | -0.04 | -0.11 | -0.02 | — | 0.01 | 0.06 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 106 | 106 | 141 | 141 | 143 | 144 | 146 | 190 |
| Reserves | -131 | -144 | -162 | -179 | -203 | -219 | -220 | -229 |
| Total liabilities | 2 | 2 | 2 | 7 | 30 | 38 | 51 | 35 |
| Total assets | 23 | 14 | 31 | 22 | 27 | 27 | 45 | 71 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8 | -9 | -16 | -14 | -18 | -17 | 27 | -12 |
| Cash from investing | 0 | — | — | — | — | — | — | — |
| Cash from financing | 2 | -0 | 32 | 5 | 21 | 7 | -14 | 23 |
| Net cash flow | -5 | -9 | 17 | -9 | 3 | -11 | 13 | 10 |
Insider filings
103 filings between Oct 31, 2025 and Oct 12, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$11.90M
19 sales by 6 insiders
74% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 45
- Award — granted as compensation
- 39
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Southpoint Capital Advisors LP | — | $9.71M | Dec 24, 2025 |
| Raykov Rosty | — | $948.8K | Sep 1, 2026 |
| Andrade Robert | — | $883.5K | Aug 27, 2026 |
| Brughera Marco Maria | — | $160.0K | Sep 15, 2026 |
| Sayad Pierre Sargis | — | $146.2K | Aug 31, 2026 |
| RALLIS CHRIS A | — | $58.8K | May 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 12, 2026 | Cioffi Christiana Marie Chief Strategy Officer | Award | 3,946 | $21.8K |
| Oct 12, 2026 | Andrade Robert CHIEF FINANCIAL OFFICER | Award | 3,846 | $21.3K |
| Oct 12, 2026 | Evans Terry L Chief Commercial Officer | Award | 2,326 | $12.9K |
| Oct 12, 2026 | Hackman Jeffrey S. Chief Executive Officer | Award | 2,224 | $12.3K |
| Oct 12, 2026 | Sayad Pierre Sargis Chief Medical Officer | Award | 3,846 | $21.3K |
| Sep 30, 2026 | Hackman Jeffrey S. Chief Executive Officer | Award | 1,159 | $0 |
| Sep 30, 2026 | Cioffi Christiana Marie Chief Strategy Officer | Award | 156 | $0 |
| Sep 30, 2026 | Andrade Robert CHIEF FINANCIAL OFFICER | Award | 1,703 | $0 |
| Sep 30, 2026 | Evans Terry L Chief Commercial Officer | Award | 168 | $0 |
| Sep 30, 2026 | Sayad Pierre Sargis Chief Medical Officer | Award | 168 | $0 |
| Sep 15, 2026 | Brughera Marco Maria Director | Sale 10b5-1 plan | 15,545 | $160.0K |
| Sep 15, 2026 | Brughera Marco Maria Director | Option exercise 10b5-1 plan | 15,545 | $32.8K |
| Sep 1, 2026 | Raykov Rosty Insider | Sale 10b5-1 plan | 10,000 | $121.1K |
| Aug 31, 2026 | Raykov Rosty Insider | Award 10b5-1 plan | 2,778 | $0 |
| Aug 31, 2026 | Sayad Pierre Sargis Chief Medical Officer | Award | 168 | $0 |
| Aug 31, 2026 | Andrade Robert CHIEF FINANCIAL OFFICER | Award | 1,703 | $0 |
| Aug 31, 2026 | Evans Terry L Chief Commercial Officer | Award | 168 | $0 |
| Aug 31, 2026 | Cioffi Christiana Marie Chief Strategy Officer | Award | 156 | $0 |
| Aug 31, 2026 | Hackman Jeffrey S. Chief Executive Officer | Award | 1,159 | $0 |
| Aug 31, 2026 | Sayad Pierre Sargis Chief Medical Officer | Sale | 12,000 | $146.2K |
| Aug 28, 2026 | Andrade Robert CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 21,928 | $111.8K |
| Aug 27, 2026 | Andrade Robert CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 75,000 | $883.5K |
| Aug 3, 2026 | Raykov Rosty Insider | Sale 10b5-1 plan | 10,000 | $95.8K |
| Jul 31, 2026 | Cioffi Christiana Marie Chief Strategy Officer | Award | 156 | $0 |
| Jul 31, 2026 | Raykov Rosty Insider | Award | 2,778 | $0 |
| Jul 31, 2026 | Sayad Pierre Sargis Chief Medical Officer | Award | 168 | $0 |
| Jul 31, 2026 | Evans Terry L Chief Commercial Officer | Award | 168 | $0 |
| Jul 31, 2026 | Hackman Jeffrey S. Chief Executive Officer | Award | 1,159 | $0 |
| Jul 31, 2026 | Andrade Robert CHIEF FINANCIAL OFFICER | Award | 1,703 | $0 |
| Jul 1, 2026 | Raykov Rosty Insider | Sale 10b5-1 plan | 9,599 | $99.9K |
| Jul 1, 2026 | Raykov Rosty Insider | Option exercise 10b5-1 plan | 15,597 | $38.2K |
| Jul 1, 2026 | Raykov Rosty Insider | Award 10b5-1 plan | 2,778 | $0 |
| Jun 30, 2026 | Cioffi Christiana Marie Chief Strategy Officer | Award | 156 | $0 |
| Jun 30, 2026 | Sayad Pierre Sargis Chief Medical Officer | Award | 168 | $0 |
| Jun 30, 2026 | Evans Terry L Chief Commercial Officer | Award | 168 | $0 |
| Jun 30, 2026 | Hackman Jeffrey S. Chief Executive Officer | Award | 1,159 | $0 |
| Jun 30, 2026 | Andrade Robert CHIEF FINANCIAL OFFICER | Award | 1,703 | $0 |
| Jun 1, 2026 | Raykov Rosty Director | Sale 10b5-1 plan | 9,747 | $93.8K |
| Jun 1, 2026 | Raykov Rosty Director | Option exercise 10b5-1 plan | 15,597 | $38.2K |
| May 31, 2026 | Raykov Rosty Director | Award 10b5-1 plan | 2,778 | $0 |
| May 31, 2026 | Andrade Robert CHIEF FINANCIAL OFFICER | Award | 1,703 | $0 |
| May 31, 2026 | Cioffi Christiana Marie Chief Strategy Officer | Award | 156 | $0 |
| May 31, 2026 | Sayad Pierre Sargis Chief Medical Officer | Award | 168 | $0 |
| May 31, 2026 | Evans Terry L Chief Commercial Officer | Award | 168 | $0 |
| May 31, 2026 | Hackman Jeffrey S. Chief Executive Officer | Award | 1,159 | $0 |
| May 11, 2026 | RALLIS CHRIS A Director | Sale 10b5-1 plan | 8,346 | $58.8K |
| May 11, 2026 | RALLIS CHRIS A Director | Option exercise 10b5-1 plan | 14,344 | $35.0K |
| May 1, 2026 | Raykov Rosty Director | Option exercise 10b5-1 plan | 15,598 | $38.2K |
| May 1, 2026 | Raykov Rosty Director | Sale 10b5-1 plan | 10,781 | $69.8K |
| Apr 30, 2026 | Evans Terry L Chief Commercial Officer | Option exercise | 168 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for FENNEC PHARMACEUTICALS INC.
Free account. Everything above stays public.
Write why you follow FENNEC PHARMACEUTICALS INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading